已收盘 02-27 16:00:00 美东时间
0.000
NaN.00%
Castle Biosciences granted 66 employees RSUs covering 135,978 shares as inducement for employment, vesting over four years. The company offers innovative diagnostics for skin cancers, Barrett’s esophagus, and uveal melanoma, with R&D programs for other high-need diseases.
06-19 11:00
Castellum, Inc. announced the pricing of a $5.0 million public offering of 4,166,667 units at $1.20 per unit. Each unit includes one share of common stock and a warrant exercisable at $1.22 per share for 60 days. Proceeds will be used for working capital and general corporate purposes. The offering is led by Maxim Group LLC, with closing expected on June 13, 2025.
06-12 13:00
Castellum, Inc. 宣布提前15个月偿还了与Buckhout Trust的可转债,显著改善了财务状况,长期债务从1200万美元减少至500万美元以下,为业务增长和服务客户释放了资源。公司专注为联邦政府提供网络安全、电子战及软件工程服务。
06-05 10:45
Castellum, Inc.'s CEO Glen Ives has been invited to present at the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow," organized by Maxim Group LLC, June 3-5, 2025. The conference will explore how emerging technologies like quantum computing and AI are shaping the future across industries. Castellum specializes in cybersecurity, electronic warfare, and software engineering services for the federal government.
06-02 10:45
Castellum, Inc. announced its 2025 annual stockholders meeting will be held on May 28, 2025, at 10:00 a.m. (Eastern Time) in Tysons, VA, with virtual access via phone. Shareholders of record as of March 21, 2025, are eligible to attend and vote. Management will host a presentation and Q&A session afterward.
05-27 10:45